CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

Relapsed/refractory acute myeloid leukemia (AML) patients generally have a dismal prognosis and the treatment remains challenging. Due to the expression of CD7 on 30% AML and not on normal myeloid and erythroid cells, CD7 is an attractive target for immunotherapy of AML. CD7-targeted CAR T-cells had...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xuanqi, Dai, Haiping, Cui, Qingya, Li, Zheng, Shen, Wenhong, Pan, Jinlan, Shen, Hongjie, Ma, Qinfen, Li, Mengyun, Chen, Sifan, Chen, Juncheng, Zhu, Xiaming, Meng, Huimin, Yang, Lin, Wu, Depei, Tang, Xiaowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523980/
https://www.ncbi.nlm.nih.gov/pubmed/36175988
http://dx.doi.org/10.1186/s40164-022-00318-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523980/
https://www.ncbi.nlm.nih.gov/pubmed/36175988
http://dx.doi.org/10.1186/s40164-022-00318-6

Ejemplares similares